M. Harada‐Shiba

发表

Combination of chondroitin sulfate and polyplex micelles from Poly(ethylene glycol)-poly{N'-[N-(2-aminoethyl)-2-aminoethyl]aspartamide} block copolymer for prolonged in vivo gene transfection with reduced toxicity.

K. Kataoka, K. Itaka, S. Uchida, 2011, Journal of controlled release : official journal of the Controlled Release Society.

Development of a 2′,4′-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo

T. Yamaoka, S. Obika, M. Harada‐Shiba, 2012, Molecular therapy. Nucleic acids.

Mice with a Deletion in the Gene for CCAAT/Enhancer-binding Protein β Have an Attenuated Response to cAMP and Impaired Carbohydrate Metabolism*

V. Poli, J. Friedman, S. Liu, 2001, The Journal of Biological Chemistry.

Mild intrauterine hypoperfusion reproduces neurodevelopmental disorders observed in prematurity

M. Tsuji, M. Harada‐Shiba, J. Coq, 2016, Scientific Reports.

Circulating Furin-Cleaved Proprotein Convertase Subtilisin/Kexin Type 9 Concentration Predicts Future Coronary Events in Japanese Subjects

Y. Kokubo, S. Yasuda, M. Harada‐Shiba, 2021, JACC. Asia.

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).

J. Car, H. Schunkert, S. Yamashita, 2018, Atherosclerosis.

Efficient reduction of serum cholesterol by combining a liver-targeted gene delivery system with chemically modified apolipoprotein B siRNA.

T. Yamaoka, S. Obika, M. Harada‐Shiba, 2012, Journal of controlled release : official journal of the Controlled Release Society.

Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017

S. Yamashita, T. Okamura, H. Arai, 2018, Journal of atherosclerosis and thrombosis.

Special Report Guidelines for the Management of Familial Hypercholesterolemia

S. Yamashita, T. Okamura, H. Arai, 2012 .

Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes

Kiyoko Kato, S. Obchoei, S. Obika, 2017, Molecular therapy. Nucleic acids.

Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia.

M. Harada‐Shiba, T. Abumiya, H. Kato, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody

M. Krempf, G. Luc, P. Hopkins, 2015, Circulation. Cardiovascular genetics.

Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.

D. Ledbetter, J. Knowles, D. Rader, 2018, Journal of the American College of Cardiology.

Management of type IIb dyslipidemia.

S. Yamashita, H. Sone, H. Arai, 2012, Journal of atherosclerosis and thrombosis.

Increase in secretory sphingomyelinase activity and specific ceramides in the aorta of apolipoprotein E knockout mice during aging.

Keiko Kobayashi, M. Harada‐Shiba, H. Kikuzaki, 2013, Biological & pharmaceutical bulletin.

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy

F. Otsuka, S. Yasuda, K. Tsujita, 2021, Journal of the American Heart Association.

Additive Effects of Drinking Habits and a Susceptible Genetic Polymorphism on Cholesterol Efflux Capacity

Panayiotis D. Megaloikonomos, M. Harada‐Shiba, K. Oniki, 2022, Journal of atherosclerosis and thrombosis.

What Arteries are Affected in Familial Hypercholesterolemia?

M. Harada‐Shiba, 2019, Journal of atherosclerosis and thrombosis.

Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia.

S. Yokoyama, Y. Yoshimasa, H. Tomoike, 2010, Journal of atherosclerosis and thrombosis.

Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel

M. Banach, G. Watts, K. Widhalm, 2021, Journal of clinical medicine.

Therapy with siRNA for Vegf-c but not for Vegf-d suppresses wide-spectrum organ metastasis in an immunocompetent xenograft model of metastatic mammary cancer.

M. Harada‐Shiba, M. Shibata, J. Morimoto, 2013, Anticancer research.

Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.

A. Takahashi, M. Harada‐Shiba, H. Makino, 2016, Journal of clinical lipidology.

Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe

M. Harada‐Shiba, A. Ohtake, H. Suganami, 2017, Journal of atherosclerosis and thrombosis.

Association between Achilles Tendon Softness and Atherosclerotic Cardiovascular Disease in Patients with Familial Hypercholesterolemia

K. Matsuki, K. Hosoda, M. Harada‐Shiba, 2022, Journal of atherosclerosis and thrombosis.

Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study

S. Yamashita, H. Daida, H. Arai, 2021, Journal of atherosclerosis and thrombosis.

Familial Hypercholesterolemia in Patients with Acute Coronary Syndrome: Genetic Insights from EXPLORE-J

A. Hirayama, H. Arai, Masato Nakamura, 2021, Journal of atherosclerosis and thrombosis.

A Resuscitated Case of Acute Myocardial Infarction with both Familial Hypercholesterolemia Phenotype Caused by Possibly Oligogenic Variants of the PCSK9 and ABCG5 Genes and Type I CD36 Deficiency

M. Furuhashi, T. Miura, H. Hattori, 2021, Journal of atherosclerosis and thrombosis.

Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study.

A. Hirayama, H. Arai, Y. Murakami, 2018, Atherosclerosis.

Achilles Tendon Ultrasonography for Diagnosis of Familial Hypercholesterolemia Among Japanese Subjects.

S. Kihara, K. Hosoda, M. Harada‐Shiba, 2017, Circulation journal : official journal of the Japanese Circulation Society.

Development of hypertriglyceridemia due to GPIHBP1 autoantibodies prior to clinical diagnosis of systemic lupus erythematosus in a 14-year-old girl.

K. Nakajima, M. Harada‐Shiba, M. Murakami, 2022, Allergology international : official journal of the Japanese Society of Allergology.

Gene Transfer and Target Diseases

M. Harada‐Shiba, 2005 .

Current Diagnosis and Management of Primary Chylomicronemia

H. Daida, K. Matsuki, S. Yokoyama, 2021, Journal of atherosclerosis and thrombosis.

Diagnosis and management of type I and type V hyperlipoproteinemia.

S. Yamashita, H. Sone, H. Arai, 2012, Journal of atherosclerosis and thrombosis.

Association of Kidney Function with Serum Levels of Cholesterol Absorption and Synthesis Markers: The CACHE Study CKD Analysis

S. Yamashita, Y. Kihara, K. Matsuki, 2022, Journal of atherosclerosis and thrombosis.

Pathological and molecular analyses of atherosclerotic lesions in ApoE-knockout mice

M. Harada‐Shiba, M. Shibata, K. Maemura, 2017, Medical Molecular Morphology.

Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration.

J. Car, H. Schunkert, S. Yamashita, 2016, Atherosclerosis. Supplements.

Apheresis technology for prevention and regression of atherosclerosis: an overview.

M. Harada‐Shiba, A. Yamamoto, A. Kawaguchi, 1997, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action.

C. Aguilar-Salinas, G. Mensah, G. Watts, 2020, JAMA cardiology.

Guidelines for the management of familial hypercholesterolemia.

S. Yamashita, T. Okamura, H. Arai, 2012, Journal of atherosclerosis and thrombosis.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.

M. Harada‐Shiba, Y. Uchigata, T. Nakagami, 2017, Journal of clinical lipidology.

Acute Cholesterol-Lowering Effect of Exendin-4 inLdlr−/− and C57BL/6J Mice

Y. Hayashi, M. Harada‐Shiba, T. Nakagami, 2022, Journal of atherosclerosis and thrombosis.

Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target.

S. Yamashita, K. Shimamoto, Y. Kiyohara, 2008, Journal of atherosclerosis and thrombosis.

Switching from lipoprotein apheresis to evolocumab in FH siblings on hemodialysis: case reports and discussion

M. Harada‐Shiba, K. Tamura, Takeo Ishii, 2021, CEN Case Reports.

C-reactive protein uptake by macrophage cell line via class-A scavenger receptor.

T. Sawamura, A. Kakino, Yuko Sato, 2010, Clinical chemistry.

Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japanese Patients with Familial Hypercholesterolemia: A Subanalysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study

S. Yamashita, H. Daida, H. Arai, 2021, Journal of atherosclerosis and thrombosis.

Hybrid Cell–Gene Therapy for Pulmonary Hypertension Based on Phagocytosing Action of Endothelial Progenitor Cells

Y. Tabata, N. Mochizuki, H. Mori, 2003, Circulation.

Adrenomedullin Gene Transfer Induces Therapeutic Angiogenesis in a Rabbit Model of Chronic Hind Limb Ischemia: Benefits of a Novel Nonviral Vector, Gelatin

W. Shimizu, Y. Tabata, H. Mori, 2004, Circulation.

Current Diagnosis and Management of Tangier Disease

S. Yamashita, K. Matsuki, K. Tsukamoto, 2021, Journal of atherosclerosis and thrombosis.

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

G. Francis, Qian Wang, D. Gaudet, 2021, The Lancet.

Familial hypercholesterolaemia: a global call to arms

J. Car, H. Schunkert, C. Aguilar-Salinas, 2015 .

Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan.

S. Yamashita, T. Okamura, H. Arai, 2012, Journal of atherosclerosis and thrombosis.

Response of 3-hydroxy-3-methylglutaryl CoA reductase to l-triiodothyronine in cultured fibroblasts from FH homozygotes.

M. Harada‐Shiba, A. Yamamoto, S. Tajima, 1995, Atherosclerosis.

How Can We Improve the Diagnosis Rate of Familial Hypercholesterolemia by Amending Diagnosis Criteria?

M. Harada‐Shiba, 2021, Circulation journal : official journal of the Japanese Circulation Society.

Achilles Tendon Softness as a New Tool for Diagnosing Familial Hypercholesterolemia.

K. Hosoda, M. Harada‐Shiba, M. Hori, 2021, JACC. Cardiovascular imaging.

Defining patients at extremely high risk for coronary artery disease in heterozygous familial hypercholesterolemia.

T. Okamura, S. Yokoyama, M. Harada‐Shiba, 2012, Journal of atherosclerosis and thrombosis.

How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?

M. Harada‐Shiba, Y. Kataoka, T. Doi, 2022, Journal of atherosclerosis and thrombosis.

Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study

S. Yamashita, H. Daida, H. Arai, 2021, Journal of atherosclerosis and thrombosis.

Prospective Registry Study of Primary Dyslipidemia (PROLIPID): Rationale and Study Design

H. Arai, S. Ishibashi, H. Tada, 2021, Journal of atherosclerosis and thrombosis.

Familial Hypercholesterolemia and Lipoprotein Apheresis

K. Matsuki, K. Hosoda, M. Harada‐Shiba, 2019, Journal of atherosclerosis and thrombosis.

Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study

G. Francis, R. Hegele, M. Reijman, 2022, The Lancet.

Homozygous Familial Hypercholesterolemia

H. Daida, K. Matsuki, S. Yokoyama, 2021, Journal of atherosclerosis and thrombosis.

Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes.

C. Sirtori, E. Manzato, D. Noto, 2018, Journal of the American College of Cardiology.

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.

G. Watts, F. Raal, R. Santos, 2017, The lancet. Diabetes & endocrinology.

Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation

Y. Izumiya, K. Sakamoto, S. Nagamatsu, 2018, Internal medicine.

Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia

A. Nohara, M. Harada‐Shiba, K. Ikewaki, 2017, Journal of atherosclerosis and thrombosis.

Homozygous familial hypercholesterolemia Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia

A. Nohara, M. Harada‐Shiba, K. Ikewaki, 2017 .

Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.

T. Nagai, S. Yasuda, S. Kawakami, 2017, Journal of clinical lipidology.

Efficacy and Safety of Pitavastatin in Japanese Male Children with Familial Hypercholesterolemia.

M. Harada‐Shiba, A. Ohtake, H. Suganami, 2016, Journal of atherosclerosis and thrombosis.

Effect of Statin Therapy in 4-Year-Old Dichorionic Diamniotic Twins with Familial Hypercholesterolemia Showing Multiple Xanthomas.

M. Harada‐Shiba, T. Ohta, Yoshitsune Miyagi, 2016, Journal of atherosclerosis and thrombosis.

Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.

H. Hattori, M. Harada‐Shiba, I. Kishimoto, 2015, The Journal of clinical endocrinology and metabolism.

Erratum: Long-Term Probucol Treatment Prevents Secondary Cardiovascular Events: a Cohort Study of Patients with Heterozygous Familial Hypercholesterolemia in Japan [Journal of Atherosclerosis and Thrombosis 1506 292-303]

S. Yamashita, Y. Matsuzawa, T. Kita, 2009 .

Siblings with normal LDL receptor activity and severe hypercholesterolemia.

S. Yokoyama, M. Harada‐Shiba, S. Tajima, 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

Apheresis technology for prevention and regression of atherosclerosis.

M. Harada‐Shiba, A. Yamamoto, A. Kawaguchi, 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

Long‐term Effect of Low‐density Lipoprotein Apheresis in Patients with Homozygous Familial Hypercholesterolemia

M. Harada‐Shiba, H. Makino, 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy.

M. Harada‐Shiba, A. Yamamoto, A. Kawaguchi, 2000, Atherosclerosis.

The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy

M. Harada‐Shiba, A. Yamamoto, A. Kawaguchi, 2000 .

High-density lipoprotein levels have markedly increased over the past twenty years in Japan.

H. Ueshima, S. Yokoyama, T. Miida, 2014, Journal of atherosclerosis and thrombosis.

The Roles of Genetic Analysis in the Diagnosis of Pediatric Patients with Familial Hypercholesterolemia

M. Harada‐Shiba, 2022, Journal of atherosclerosis and thrombosis.

Morphological Characteristics of Aortic Stenosis in Familial Hypercholesterolemia and Non-Familial Hypercholesterolemia in the Elderly

H. Ishibashi-Ueda, M. Harada‐Shiba, M. Hori, 2020, Journal of Integrative Cardiology Open Access.

A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects.

A. Catapano, M. Harada‐Shiba, Shazia Ali, 2020, Atherosclerosis.

How much further do we need to decrease LDL cholesterol levels in heterozygous familial hypercholesterolemia?

M. Harada‐Shiba, 2019, Atherosclerosis.

Clinical features and genetic analysis of autosomal recessive hypercholesterolemia.

S. Yokoyama, M. Harada‐Shiba, Y. Miyamoto, 2003, The Journal of clinical endocrinology and metabolism.

Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON.

A. Kiyosue, M. Harada‐Shiba, T. Teramoto, 2019, Journal of cardiology.

Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice

T. Yamaoka, S. Obika, T. Imanishi, 2012, Molecular therapy. Nucleic acids.

Changes in Coagulation Factors by Passage through a Dextran Sulfate Cellulose Column during Low-Density Lipoprotein Apheresis

M. Harada‐Shiba, M. Kuramochi, T. Omae, 1992, The International journal of artificial organs.

Disruption of Autosomal Recessive Hypercholesterolemia Gene Shows Different Phenotype In Vitro and In Vivo

S. Yokoyama, Y. Asada, S. Ishibashi, 2004, Circulation research.

Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI.

M. Harada‐Shiba, H. Kato, K. Enjyoji, 1996, Arteriosclerosis, thrombosis, and vascular biology.

VLDL/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body

Y. Masuo, M. Harada‐Shiba, Hiroshi Suzuki, 2017, Scientific Reports.

Liver-targeted siRNA delivery by polyethylenimine (PEI)-pullulan carrier.

T. Yamaoka, A. Mahara, M. Harada‐Shiba, 2010, Bioorganic & medicinal chemistry.

Phagocytic degradation of chylomicron remnants by fibroblasts from subjects with homozygous familial hypercholesterolaemia.

M. Harada‐Shiba, A. Yamamoto, A. Kawaguchi, 1997, Clinical science.

Current Diagnosis and Management of Abetalipoproteinemia

K. Matsuki, S. Yokoyama, S. Ishibashi, 2021, Journal of atherosclerosis and thrombosis.

Apolipoprotein E-knockout Mice as a Lifestyle-related Disease Model of Atherosclerosis and Non-alcoholic Fatty Liver Disease

M. Harada‐Shiba, M. Shibata, E. Shibata, 2015 .

In vivo siRNA delivery with dendritic poly(L-lysine) for the treatment of hypercholesterolemia.

T. Niidome, Y. Katayama, M. Harada‐Shiba, 2009, Molecular bioSystems.

Artificial switching of the metabolic processing pathway of an etiologic factor, β2-microglobulin, by a "navigator" molecule.

T. Yamaoka, Y. Hirano, M. Harada‐Shiba, 2020, Journal of controlled release : official journal of the Controlled Release Society.

Current concept and residual issues of lipoprotein(a) determination for a cardiovascular risk factor

M. Harada‐Shiba, Y. Hirowatari, M. Ogura, 2021, European journal of clinical investigation.

Discontinuation of LDL apheresis with evolocumab in an FH patient with a duplication of exon 2-6 in the LDLR gene.

S. Miura, S. Imaizumi, K. Saku, 2019, Journal of cardiology cases.

Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels

M. Harada‐Shiba, Y. Kataoka, T. Noguchi, 2022, Journal of the American Heart Association.

Detection of the benign c.2579C>T (p.A860V) variant of the LDLR gene in a pedigree-based genetic analysis of familial hypercholesterolemia.

M. Harada‐Shiba, M. Hori, Cheol Son, 2019, Journal of clinical lipidology.

Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia

A. Nohara, M. Harada‐Shiba, K. Ikewaki, 2019, Journal of atherosclerosis and thrombosis.

Familial hypercholesterolemia.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

Common mutations in the low-density-lipoprotein-receptor gene causing familial hypercholesterolemia in the Japanese population.

T. Funahashi, Y. Matsuzawa, T. Maruyama, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Familial hypercholesterolemia with multiple large tendinous xanthomas and advanced coronary artery atherosclerosis.

M. Harada‐Shiba, N. Ishizaka, Y. Miyamoto, 2013, Internal medicine.

A novel Thr56Met mutation of the autosomal recessive hypercholesterolemia gene associated with hypercholesterolemia.

Y. Kokubo, I. Yamanaka, T. Morisaki, 2010, Journal of atherosclerosis and thrombosis.

Deficiency of Cardiac Natriuretic Peptide Signaling Promotes Peripartum Cardiomyopathy-Like Remodeling in the Mouse Heart

K. Nakao, A. Fukamizu, T. Ikeda, 2020, Circulation.

Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.

D. Gaudet, R. Rosenson, D. Blom, 2020, Journal of the American College of Cardiology.

Intraperitoneal and intravenous deliveries are not comparable in terms of drug efficacy and cell distribution in neonatal mice with hypoxia–ischemia

H. Iida, T. Ikeda, H. Tsuda, 2015, Brain and Development.

Humoral factors secreted from adipose tissue-derived mesenchymal stem cells ameliorate atherosclerosis in Ldlr−/− mice

T. Mizuno, M. Harada‐Shiba, M. Hori, 2018, Cardiovascular research.

Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study

A. Nohara, M. Harada‐Shiba, K. Ikewaki, 2019, Journal of atherosclerosis and thrombosis.

Proteomic Analysis of Proteins Eliminated by Low‐Density Lipoprotein Apheresis

N. Minamino, M. Harada‐Shiba, I. Kishimoto, 2014, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

Lp (a) >50 mg/dl predicts atherosclerotic cardiovascular events in patients with heterozygous familial hypercholesterolemia who achieved LDL-C <2.6 mmol/l

K. Matsuki, T. Noguchi, M. Harada‐Shiba, 2020 .

Intratracheal gene transfer of adrenomedullin using polyplex nanomicelles attenuates monocrotaline-induced pulmonary hypertension in rats.

N. Nishiyama, K. Kataoka, K. Itaka, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments

K. Matsuki, T. Miida, M. Harada‐Shiba, 2021, Journal of atherosclerosis and thrombosis.

Surface Modification with Lactadherin Augments the Attachment of Sonazoid Microbubbles to Glycoprotein IIb/IIIa.

M. Harada‐Shiba, A. Kamiya, K. Otani, 2019, Ultrasound in medicine & biology.

Simplified Preparation of αvβ3 Integrin-Targeted Microbubbles Based on a Clinically Available Ultrasound Contrast Agent: Validation in a Tumor-Bearing Mouse Model.

M. Harada‐Shiba, A. Kamiya, K. Otani, 2018, Ultrasound in medicine & biology.

Guidelines on the Clinical Evaluation of Medicinal Products for Treatment of Dyslipidemia

S. Yamashita, T. Okamura, H. Arai, 2020, Journal of atherosclerosis and thrombosis.

LDL apheresis in Japan.

M. Harada‐Shiba, H. Makino, T. Tamanaha, 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Evaluations of Intravenous Administration of CD34+ Human Umbilical Cord Blood Cells in a Mouse Model of Neonatal Hypoxic-Ischemic Encephalopathy

T. Ikeda, K. Yamahara, M. Tsuji, 2017, Developmental Neuroscience.

Cell therapy for pulmonary hypertension: What is the true potential of endothelial progenitor cells? Response

Y. Tabata, N. Mochizuki, H. Mori, 2004 .

The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.

M. Harada‐Shiba, A. Yamamoto, H. Kato, 2006, Atherosclerosis.

Programmed Instability of Ligand Conjugation Manifold for Efficient Hepatocyte Delivery of Therapeutic Oligonucleotides.

S. Obika, M. Harada‐Shiba, Tsuyoshi Yamamoto, 2021, Nucleic acid therapeutics.

Long-term Effect of LDL-Apheresis on Familial Hypercholesterolemia Homozygotes

M. Harada‐Shiba, A. Yamamoto, A. Kawaguchi, 2000 .

Locked nucleic acid antisense inhibitor targeting apolipoprotein C-III efficiently and preferentially removes triglyceride from large very low-density lipoprotein particles in murine plasma.

S. Obika, M. Harada‐Shiba, M. Shibata, 2014, European journal of pharmacology.

The impact of gene variants on the thickness and softness of the Achilles tendon in familial hypercholesterolemia.

K. Hosoda, M. Harada‐Shiba, M. Hori, 2022, Atherosclerosis.

Plasmapheresis for Prevention and Regression of Coronary Atherosclerosis

M. Harada‐Shiba, M. Takamiya, A. Yamamoto, 1994, Annals of the New York Academy of Sciences.

Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides.

S. Obika, M. Harada‐Shiba, Tsuyoshi Yamamoto, 2016, Bioorganic & medicinal chemistry.

[Familial hypercholesterolemia (FH)].

M. Harada‐Shiba, A. Nagumo, 2007, Nihon rinsho. Japanese journal of clinical medicine.

Experimental Translational Research Using siRNA to Target Vascular Genesis in Inhibition of Mammary Cancer Metastasis

M. Harada‐Shiba, M. Shibata, E. Shibata, 2013 .

Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides

S. Obika, M. Harada‐Shiba, Tsuyoshi Yamamoto, 2021, Molecular therapy. Nucleic acids.

Quick nuclear transportation of siRNA and in vivo hepatic ApoB gene silencing with galactose-bearing polymeric carrier.

T. Yamaoka, M. C. Munisso, M. Harada‐Shiba, 2014, Journal of biotechnology.

Plasma constituents other than low-density lipoprotein adsorbed by dextran-sulfate column.

M. Harada‐Shiba, A. Yamamoto, S. Kojima, 1997, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

Superior Silencing by 2′,4′-BNANC-Based Short Antisense Oligonucleotides Compared to 2′,4′-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors

S. Obika, T. Imanishi, M. Harada‐Shiba, 2012, Journal of nucleic acids.

Research Article Superior Silencing by 2,4-BNA NC -Based Short Antisense Oligonucleotides Compared to2,4-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors

S. Obika, T. Imanishi, M. Harada‐Shiba, 2012 .

The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis

Y. Takikawa, M. Kusaoi, T. Okado, 2021, Therapeutic apheresis and dialysis.

Crude α-Mangostin Suppresses the Development of Atherosclerotic Lesions in Apoe-Deficient Mice by a Possible M2 Macrophage-Mediated Mechanism

M. Iinuma, M. Harada‐Shiba, M. Shibata, 2019, International journal of molecular sciences.

Development of Antisense Drugs for Dyslipidemia

M. Harada‐Shiba, Tsuyoshi Yamamoto, Fumito Wada, 2016, Journal of atherosclerosis and thrombosis.

Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.

S. Obika, M. Harada‐Shiba, Shunsuke Wada, 2016, Journal of Controlled Release.

Comparison of Angiogenic, Cytoprotective, and Immunosuppressive Properties of Human Amnion- and Chorion-Derived Mesenchymal Stem Cells

T. Ikeda, H. Tsuda, T. Soma, 2014, PloS one.

Effective gene silencing activity of prodrug-type 2'-O-methyldithiomethyl siRNA compared with non-prodrug-type 2'-O-methyl siRNA.

S. Obika, O. Nakagawa, M. Harada‐Shiba, 2018, Bioorganic & medicinal chemistry letters.

Amido-bridged nucleic acids with small hydrophobic residues enhance hepatic tropism of antisense oligonucleotides in vivo.

S. Obika, M. Harada‐Shiba, Tsuyoshi Yamamoto, 2015, Organic & biomolecular chemistry.

Hypoglycemia and impaired hepatic glucose production in mice with a deletion of the C/EBPbeta gene.

V. Poli, J. Friedman, S. Liu, 1999, The Journal of clinical investigation.

Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs.

G. Watts, K. Widhalm, M. Harada‐Shiba, 2017, Journal of clinical lipidology.

Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study

A. Hirayama, H. Arai, Masato Nakamura, 2017, BMJ Open.

Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia

H. Shimokawa, S. Yasuda, D. Onozuka, 2021, Journal of the American Heart Association.

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.

S. Humphries, S. Yamashita, G. Watts, 2016, The lancet. Diabetes & endocrinology.

Identification of a novel large duplication (exon2_6dup): copy number variation in the LDLR gene in a large family with familial hypercholesterolemia by whole-genome sequencing.

K. Hosoda, M. Harada‐Shiba, M. Hori, 2022, Journal of clinical lipidology.

Familial hypercholesterolaemia

R. Hegele, S. Gidding, R. Santos, 2017, Nature Reviews Disease Primers.

Significant gaps in awareness of familial hypercholesterolemia among physicians in selected Asia-Pacific countries: a pilot study.

G. Watts, M. Harada‐Shiba, D. Sullivan, 2015, Journal of clinical lipidology.

Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients.

A. Takahashi, K. Hosoda, M. Harada‐Shiba, 2019, Atherosclerosis.

Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J

A. Hirayama, H. Arai, Y. Murakami, 2021, Journal of atherosclerosis and thrombosis.

Human iPS cell-derived mural cells as an in vitro model of hereditary cerebral small vessel disease

D. Taura, M. Sone, R. Kalaria, 2020, Molecular Brain.

Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides

S. Obika, M. Harada‐Shiba, Tsuyoshi Yamamoto, 2021, Pharmaceutics.

Evaluation of multiple-turnover capability of locked nucleic acid antisense oligonucleotides in cell-free RNase H-mediated antisense reaction and in mice.

S. Obika, M. Harada‐Shiba, Shunsuke Wada, 2014, Nucleic acid therapeutics.

Mammary cancer gene therapy targeting lymphangiogenesis: VEGF-C siRNA and soluble VEGF receptor-2, a splicing variant

J. Ambati, M. Harada‐Shiba, M. Shibata, 2012, Medical Molecular Morphology.

Inhibition of Tumor Growth and Metastasis by a Combination of Anti-VEGF-C and Enhanced IL-12 Therapy in an Immunocompetent Mouse Mammary Cancer Model

M. Harada‐Shiba, M. Shibata, J. Morimoto, 2011 .

High performance gene delivery polymeric vector: nano-structured cationic star polymers (star vectors).

Y. Nakayama, M. Harada‐Shiba, T. Masuda, 2005, Current drug delivery.

Induced pluripotent stem cells generated from diabetic patients with mitochondrial DNA A3243G mutation

K. Nakao, D. Taura, M. Sone, 2012, Diabetologia.

Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene

K. Matsuki, A. Nohara, M. Kawashiri, 2021, Journal of atherosclerosis and thrombosis.

Dose-Dependent Effect of Intravenous Administration of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Neonatal Stroke Mice

M. Tsuji, M. Harada‐Shiba, H. Shintaku, 2018, Front. Neurol..

Oxidized Low Density Lipoprotein Induces Apoptosis in Cultured Human Umbilical Vein Endothelial Cells by Common and Unique Mechanisms*

M. Harada‐Shiba, K. Shimokado, M. Kinoshita, 1998, The Journal of Biological Chemistry.

Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction: benefit of a novel nonviral vector, cationized dextran.

Y. Tabata, K. Kangawa, J. Jo, 2006, Tissue engineering.

Association Between Cholesterol Efflux Capacity and Atherosclerotic Cardiovascular Disease in Patients With Familial Hypercholesterolemia

M. Harada‐Shiba, M. Hori, M. Ogura, 2016, Arteriosclerosis, thrombosis, and vascular biology.

Effects of intravenous administration of umbilical cord blood CD34+ cells in a mouse model of neonatal stroke

T. Ikeda, K. Yamahara, M. Tsuji, 2014, Neuroscience.

Effect of nafamostat mesilate on bradykinin generation during low-density lipoprotein apheresis using a dextran sulfate cellulose column.

M. Harada‐Shiba, M. Kuramochi, T. Omae, 1991, ASAIO transactions.

Association of ceramides in human plasma with risk factors of atherosclerosis

M. Harada‐Shiba, I. Ichi, T. Maruyama, 2006, Lipids.

Acquisition of Secretion of Transforming Growth Factor-β1 Leads to Autonomous Suppression of Scavenger Receptor Activity in a Monocyte-Macrophage Cell Line, THP-1*

M. Harada‐Shiba, S. Tajima, A. Yamamoto, 1998, The Journal of Biological Chemistry.

Association between Familial Hypercholesterolemia and Serum Levels of Cholesterol Synthesis and Absorption Markers: The CACHE Study FH Analysis

S. Yamashita, Y. Kihara, K. Matsuki, 2023, Journal of atherosclerosis and thrombosis.

Serum Values of Cholesterol Absorption and Synthesis Biomarkers in Japanese Healthy Subjects: The CACHE Study HEALTHY Analysis

S. Yamashita, Y. Kihara, K. Matsuki, 2023, Journal of atherosclerosis and thrombosis.

Polyion complex micelles as vectors in gene therapy – pharmacokinetics and in vivo gene transfer

K. Kataoka, I. Takamisawa, K. Yamauchi, 2002, Gene Therapy.

VLDL/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body

Y. Masuo, M. Harada‐Shiba, T. Takada, 2017, Scientific Reports.

Taxifolin inhibits amyloid-β oligomer formation and fully restores vascular integrity and memory in cerebral amyloid angiopathy

R. Kalaria, R. Takahashi, Hideki Ito, 2017, Journal of the Neurological Sciences.

Increase of serum uric acid levels associated with APOE ε2 haplotype: a clinico-genetic investigation and in vivo approach

N. Shinomiya, R. Okada, A. Hishida, 2021, Human Cell.

Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022

S. Yamashita, K. Matsuki, H. Tada, 2023, Journal of atherosclerosis and thrombosis.

Guidance for Pediatric Familial Hypercholesterolemia 2017

S. Yamashita, K. Yokote, A. Nohara, 2018, Journal of atherosclerosis and thrombosis.

Serum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux from macrophages

K. Shimamoto, S. Yuda, Marenao Tanaka, 2017, Scientific Reports.

Current Status of Familial LCAT Deficiency in Japan

K. Matsuki, S. Yokoyama, T. Miida, 2021, Journal of atherosclerosis and thrombosis.

Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan.

S. Yamashita, Y. Matsuzawa, T. Kita, 2008, Journal of atherosclerosis and thrombosis.

Background to discuss guidelines for control of plasma HDL-cholesterol in Japan.

S. Yamashita, H. Sone, H. Arai, 2012, Journal of atherosclerosis and thrombosis.

Human iPS cell-derived mural cells as an in vitro model of hereditary cerebral small vessel disease

D. Taura, M. Sone, R. Kalaria, 2020, Molecular Brain.

Long-term treatment with evolocumab homozygous familial hypercholesterolemia patients: Results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (Taussig)

F. Raal, R. Santos, D. Blom, 2016 .

Substantially Elevated Atherosclerotic Risks in Japanese Severe Familial Hypercholesterolemia Defined by the International Atherosclerosis Society

K. Nishimura, M. Harada‐Shiba, Y. Kataoka, 2021, JACC. Asia.

Efficacy of evolocumab (AMG 145) in patients with PCSK9 gain-of-function mutations

G. Watts, M. Harada‐Shiba, H. Makino, 2014 .

Pharmaceutical Research for Inherited Metabolic Disorders of the Liver Using Human Induced Pluripotent Stem Cell and Genome Editing Technologies.

H. Mizuguchi, T. Yamashita, M. Harada‐Shiba, 2019, Biological & pharmaceutical bulletin.

Diagnosis and Management of Sitosterolemia 2021

S. Yamashita, K. Matsuki, K. Tsukamoto, 2021, Journal of atherosclerosis and thrombosis.

Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion.

M. Harada‐Shiba, H. Soran, H. Makino, 2016, Atherosclerosis.

Effects of Dietary Cholesterol on Tissue Ceramides and Oxidation Products of Apolipoprotein B-100 in ApoE-Deficient Mice

M. Harada‐Shiba, I. Ichi, S. Kojo, 2007, Lipids.

Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022

S. Yamashita, K. Matsuki, K. Yokote, 2023, Journal of atherosclerosis and thrombosis.

Effect of modular conjugation strategy for N-acetylgalactosamine-targeted antisense oligonucleotides

S. Obika, M. Harada‐Shiba, Tsuyoshi Yamamoto, 2020, Nucleosides, nucleotides & nucleic acids.

PEGylated polyplex with optimized PEG shielding enhances gene introduction in lungs by minimizing inflammatory responses.

K. Kataoka, K. Itaka, S. Uchida, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Synthesis of Monovalent N‐Acetylgalactosamine Phosphoramidite for Liver‐Targeting Oligonucleotides

S. Obika, M. Harada‐Shiba, Tsuyoshi Yamamoto, 2019, Current protocols in nucleic acid chemistry.

Investigation into Lipid Management in Acute Coronary Syndrome Patients from the EXPLORE-J Study

A. Hirayama, H. Arai, Y. Murakami, 2019, Journal of atherosclerosis and thrombosis.

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale

A. Kiyosue, K. Tobita, M. Harada‐Shiba, 2017, Lipids in Health and Disease.

Amplified Risk of Intracranial Artery Stenosis/Occlusion Associated With RNF213 p.R4810K in Familial Hypercholesterolemia

K. Nishimura, M. Harada‐Shiba, M. Ihara, 2023, JACC. Asia.

The first Japanese cases of familial hypercholesterolemia due to a known pathogenic APOB gene variant, c.10580 G>A: p.(Arg3527Gln).

A. Takahashi, M. Harada‐Shiba, M. Hori, 2020, Journal of clinical lipidology.

A catalog of the pathogenic mutations of LDL receptor gene in Japanese familial hypercholesterolemia.

A. Nohara, M. Kawashiri, H. Tada, 2020, Journal of clinical lipidology.

2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

D. Gaudet, R. Hegele, F. Raal, 2023, European heart journal.

First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias.

M. Harada‐Shiba, H. Soran, U. Julius, 2015, Atherosclerosis. Supplements.

Relationship between Diabetes Mellitus and Serum Lathosterol and Campesterol Levels: The CACHE Study DM Analysis

S. Yamashita, Y. Kihara, K. Matsuki, 2022, Journal of atherosclerosis and thrombosis.

Uptake of oxidized low-density lipoprotein in a THP-1 cell line lacking scavenger receptor A.

M. Harada‐Shiba, A. Yamamoto, T. Yamamura, 2001, Atherosclerosis.

Comprehensive analysis of mechanism underlying hypouricemic effect of glucosyl hesperidin.

M. Harada‐Shiba, H. Hirata, M. Ogura, 2019, Biochemical and biophysical research communications.

A. Kiyosue, K. Tobita, M. Harada‐Shiba, 2017, Lipids in Health and Disease.

Clinical Inertia in the Management of Hypercholesterolemia: What Clinicians Need to do.

M. Harada‐Shiba, M. Ogura, 2016, Journal of atherosclerosis and thrombosis.

Relationship between Diabetes Mellitus and Serum Lathosterol and Campesterol Levels: The CACHE Study DM Analysis

S. Yamashita, Y. Kihara, K. Matsuki, 2023 .

Impact of Familial Hypercholesterolemia Diagnosis in Real-World Data

M. Harada‐Shiba, 2023, Journal of Atherosclerosis and Thrombosis.

Elevated atherogenic index following oral administration of quaternized polyamine nanogels.

A. Kikuchi, Y. Nagasaki, M. Harada‐Shiba, 2014, Colloids and surfaces. B, Biointerfaces.

Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.

D. Ledbetter, J. Knowles, D. Rader, 2018, Journal of the American College of Cardiology.

Intraperitoneal and intravenous deliveries are not comparable in terms of drug efficacy and cell distribution in neonatal mice with hypoxia–ischemia

H. Iida, T. Ikeda, H. Tsuda, 2015, Brain and Development.

LDL apheresis in Japan.

M. Harada‐Shiba, H. Makino, T. Tamanaha, 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

C-reactive protein uptake by macrophage cell line via class-A scavenger receptor.

T. Sawamura, A. Kakino, Yuko Sato, 2010, Clinical chemistry.

Clinical Characteristics of Homozygous Familial Hypercholesterolemia in Japan

S. Yamashita, K. Matsuki, T. Miida, 2023, JACC. Asia.

The benign c.344G > A: p.(Arg115His) variant in the LDLR gene interpreted from a pedigree-based genetic analysis of familial hypercholesterolemia

A. Takahashi, M. Harada‐Shiba, M. Hori, 2020, Lipids in Health and Disease.

Rebound Curve Following LDL-Apheresis Reflects Catabolic Rate of Plasma Cholesterol And The Synthetic Rate of Lp(A)

M. Harada‐Shiba, A. Yamamoto, S. Kojima, 1996 .

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).

G. Francis, Qian Wang, D. Gaudet, 2021, Lancet.

Dynamic and static control of the off-target interactions of antisense oligonucleotides using toehold chemistry

M. Harada‐Shiba, K. Ohyama, N. Aibara, 2023, Nature communications.

Multimodality assessment of left ventricular dysfunction in Takayasu arteritis and familial hypercholesterolaemia

T. Hanafusa, T. Anzai, S. Yasuda, 2017, ESC Heart Failure.

Clinical features and genetic analysis of autosomal recessive hypercholesterolemia.

S. Yokoyama, M. Harada‐Shiba, Y. Miyamoto, 2003, The Journal of clinical endocrinology and metabolism.